Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model-Reference-Cited by-同舟云学术

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model

Published:2019-08-07 Issue:504 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Anthony-Gonda Kim¹^ORCID,Bardhi Ariola²^ORCID,Ray Alex²^ORCID,Flerin Nina²^ORCID,Li Mengyan²^ORCID,Chen Weizao³,Ochsenbauer Christina⁴^ORCID,Kappes John C.⁴⁵^ORCID,Krueger Winfried¹^ORCID,Worden Andrew¹^ORCID,Schneider Dina¹,Zhu Zhongyu¹,Orentas Rimas¹^ORCID,Dimitrov Dimiter S.⁶^ORCID,Goldstein Harris²^ORCID,Dropulić Boro¹^ORCID

Affiliation:

1. Lentigen, a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.

2. Department of Microbiology and Immunology and Pediatrics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

3. Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.

4. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

5. Birmingham Veterans Affairs Medical Center, Research Service, Birmingham, AL 35294, USA.

6. Center for Antibody Therapeutics, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Abstract

Multispecific duoCAR-T cells potently suppress HIV infection in a humanized mouse model.

Funder

National Institute on Drug Abuse

National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference56 articles.

1. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

2. Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

3. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

4. A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy

5. Gene transfer in humans using a conditionally replicating lentiviral vector

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies;Biomarker Research;2024-07-29

2. CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges;Infectious Diseases & Immunity;2024-07-25

3. The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases;Med;2024-06

4. Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV;Current Opinion in Infectious Diseases;2024-05-31

5. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study;Cell Discovery;2024-05-14